Previous close | 151.00 |
Open | 149.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 149.00 - 151.02 |
52-week range | 118.16 - 152.66 |
Volume | |
Avg. volume | 4,406 |
Market cap | 234.83B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.29 |
EPS (TTM) | 4.05 |
Earnings date | 25 July 2024 |
Forward dividend & yield | 2.86 (1.89%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.